-+ 0.00%
-+ 0.00%
-+ 0.00%

Galecto Initiates Clinical Development Of Anti-mutCALR Pipeline Candidates

Benzinga·01/12/2026 13:17:06
Listen to the news
  • DMR-001, a potentially best-in-class mutant calreticulin ("mutCALR") targeting monoclonal antibody, on track for expected IND submission, or equivalent, in mid-2026 with anticipated first-in-human dosing via subcutaneous administration
  • Recent addition of deep hematology/oncology drug development experience with the appointment of a Chief Operating Officer and Chief Medical Officer
  • Pipeline of additional candidates advancing to the clinic, with first IND submission of DMR-002 expected in second half of 2026
  • Cash balance, following $285M raised in the November PIPE, provides financial runway into 2029 to support multiple data milestones, including Ph1 clinical proof-of-concept data for DMR-001 anticipated in 2027